Initiate Phase 2 study for Bitopertin in Diamond-Blackfan Anemia

Delivered after the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 23 Jan 2023
Due: 30 Jun 2023
Delivered: July 2023

Deadline
Met
Late
Not met
Today

What the company said

“Phase 2 in DBA – init. 1H’23”

SourceDisc Medicine, Inc. Form 8-K press release, 2023-01-23
FilingSEC filing index
Deadline as stated1H’23
Deadline used30 Jun 2023, the last day of the stated period
TypeProject
Permanent referenceKI-C-2023-IRON-002120
Cite as https://keptindex.org/c/KI-C-2023-IRON-002120/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company initiated a Phase 1/2 study for Bitopertin in Diamond-Blackfan Anemia in July 2023, which occurred after the first half of 2023 deadline.

A
Disc Medicine, Inc. 8-K filed 2023-08-11 Regulatory filing · published 11 Aug 2023 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint 049d9fef4bf8
“Initiated and enrolled first patient in an NIH-sponsored Phase 1/2 study of bitopertin in patients with Diamond-Blackfan Anemia in July 2023” ✓ confirmed on the page

Market reaction: the shares moved +4.8% against the S&P 500 over the three sessions around the disclosure (10 Aug 2023 to 15 Aug 2023). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

2 versions

Version 1 · original · stated 23 Jan 2023

Deadline 30 Jun 2023 (“1H’23”)
Version 2 · stated 14 Feb 2023

Deadline 30 Jun 2023 (“in the first half of 2023”) · wording expected

“Disc expects to initiate a separate trial in Diamond-Blackfan Anemia (DBA) patients in the first half of 2023.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Initiate
Deliverable: Phase 2 study for Bitopertin in Diamond-Blackfan Anemia
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Met”.
Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2023-IRON-002120 · Corrections policy